A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone

References

• Belchetz P. E., Plant T. M., Nakai Y., Keogh E. J., Knobil E. Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin releasing hormone. Science 1978; 202: 631
   PubMed Web of Science ®Google Scholar
• Meldrum D. R., Chang R. J., Lu J., Vale W., Rivier J., Judd H. L. Medical oophorectomy using a long-acting GnRH agonist: a possible new approach to treatment of endometriosis. J. Clin. Endocrinol. Metab. 1982; 54: 1081–3
   PubMed Web of Science ®Google Scholar
• Barbieri R. L. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy. Am. J. Obstet. Gynecol. 1990; 162: 593–5
   PubMedGoogle Scholar
• Saltiel E., Garabedian-Ruffalo S. M. Pharmacologic management of endometriosis. Clin. Pharm. 1991; 10: 518–31
   PubMedGoogle Scholar
• Dawood M. Y. Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet. Gynecol Scand. Suppl 1994; 159: 22–34
   Google Scholar
• Jacobson J., Harris S. R., Bullingham E. S. Low dose intranasal nafarelin for the treatment of endometriosis. Acta Obstet. Gynecol. Scand. 1994; 73: 144–50
   Web of Science ®Google Scholar
• Edmonds D. K., Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis?. Br. J. Obstet. Gynaecol. 1994; 101(Suppl. 10)24–6
   Google Scholar
• Friedman A. J., Hornstein M. D. Gonadotropin-releasing hormone agonist plus estrogen-progestin ‘add-back’ therapy for endo-metriosis-related pelvic pain. Fertil. Steril. 1993; 60: 236–41
   PubMed Web of Science ®Google Scholar
• Leather A. T., Studd J. W. W., Watson N. R., Holland E. F. N. The prevention of bone loss in young women treated with GnRH analogs with ‘add-back’ estrogen therapy. Obstet. Gynecol. 1993; 81: 104–7
   PubMed Web of Science ®Google Scholar
• Surrey E. S. Steroidal and nonsteroidal ‘add-back’ therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fertil. Steril. 1995; 64: 673–85
   PubMed Web of Science ®Google Scholar
• American Fertility Society. Revised American Fertility Society classification of endometriosis. Fertil. Steril. 1985; 43: 351
   PubMed Web of Science ®Google Scholar
• Henzl M. R., Corson S. L., Moghissi K., But-tram V. C., Bergqvist C., Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N. Engl. J. Med. 1988; 318: 485–9
   PubMed Web of Science ®Google Scholar
• Kennedy S. H., Williams I. A., Brodribb J., Barlow D. H., Shaw R. W. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil. Steril. 1990; 53: 998–1003
   PubMed Web of Science ®Google Scholar
• The Nafarelin European Endometriosis Trial. (NEET) Groups (Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil. Steril. 1992; 57: 514–22
   Google Scholar
• Adashi E. Y. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal ‘add-back’ paradigm. Hum. Re-prod. 1994; 9: 1380–97
   PubMedGoogle Scholar
• Venturing P. L., Fasce V., Costantini S., Anserini P., Cucuccio S., de Cecco L. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. Fertil. Steril. 1990; 54: 1021–7
   Google Scholar
• Waller K. G., Shaw R. W. Gonadotropin-releasing hormone analogs for the treatment of endometriosis: long-term follow-up. Fertil. Steril. 1993; 59: 511–14
   PubMed Web of Science ®Google Scholar
• Johansen J. S., Riis B. J., Hassager C., Moen M., Jacobsen J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 1988; 67: 701–6
   PubMed Web of Science ®Google Scholar
• Ravn P., Bergqvist A., Hansen M. A., Over-gaard K., Christiansen C. Treatment of endometriosis with the luteinizing hormone-releasing hormone agonist nafarelin. Effect on bone turnover and bone mass. Maturitas 1994; 1: 11–17
   Google Scholar
• Riis B. J., Christiansen C., Johansen J. S., Jacobsen J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?. J. Clin. Endocrinol. Metab. 1990; 70: 920–40
   PubMed Web of Science ®Google Scholar
• Surrey E. S., Gambone J. C., Lu J. K. H., Judd H. L. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil. Steril. 1990; 53: 620–6
   Google Scholar
• Surrey E. S., Judd H. L. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J. Clin. Endocrinol. Metab. 1992; 75: 558–63
   Google Scholar
• Eldred J. M., Haynes P. J., Thomas E. J. A randomized double-blind placebo-controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin. Endocrinol. 1992; 37: 354–9
   Google Scholar
• Monroe S. E., Blumenfeld Z., Andreyko J. L., Schriock E., Henzl M. R., Jaffrey R. B. Dose-dependent inhibition of pituitary-ovarian function during administration of gonadotropin-releasing hormone agonist analog (nafarelin). J. Clin. Endocrinol. Metab. 1986; 63: 1334–41
   Google Scholar
• Bergqvist A., Landgren B.-M., Diczfalusy E. A clinical, pharmacokinetic and pharmacodynamic study of three progestogens in the treatment of endometriosis. New Trends Obstet. Gynecol. 1988; 4: 65–84
   Google Scholar
• Barbieri R. L. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. 1992; 166: 740–5
   PubMed Web of Science ®Google Scholar